开放气道下急性呼吸窘迫综合征治疗前后肺部微生物组的变化
该回顾性研究纳入江门市中心医院ICU 2019年2月至2020年1月收治的严重肺炎所致ARDS患者,分为治疗前组24例、治疗后生存组17例和治疗后死亡组7例,另设同期轻症肺部感染非ARDS对照25例,比较四组肺部微生物组。结果显示死亡组大肠埃希菌和白色念珠菌阳性率显著高于生存组[57.1%(4/7)vs. 5.9%(1/17)和57.1%(4/7)vs. 0%(0/7),均P<0.05];Hydrobacter在死亡组低于生存组和对照组[14.3%(1/7)vs. 94.1%(16/17)和14.3%(1/7)vs. 96.0%(24/25),均P<0.05]。作者认为大肠埃希菌或白色念珠菌增多、肠杆菌目背景菌增多可能是ARDS死亡的危险因素,Hydrobacter可能是生存保护因素。
要点
- ARDS治疗后死亡组大肠埃希菌阳性率57.1%(4/7),显著高于生存组5.9%(1/17),P<0.05。
- ARDS治疗后死亡组白色念珠菌阳性率57.1%(4/7),显著高于生存组0%(0/7),P<0.05。
- Hydrobacter在ARDS治疗后死亡组为14.3%(1/7),低于生存组94.1%(16/17)和对照组96.0%(24/25),均P<0.05。
- 肠杆菌目中的爱德华菌属、肠杆菌科、埃希菌属、克雷伯菌属、克吕沃尔菌属、莱略特菌属、泛菌属、拉乌尔菌属在死亡组较治疗前组、生存组和对照组增多,可能为死亡危险因素。
- 作者认为Hydrobacter可能是ARDS生存保护因素,能否作为新型治疗值得进一步研究。
适用人群与场景
- 江门市中心医院ICU 2019年2月至2020年1月收治的严重肺炎所致ARDS患者,分为治疗前组24例、治疗后生存组17例、治疗后死亡组7例。
- 同期ICU收治的轻症肺部感染且非ARDS患者25例作为对照组。
研究设计与关键结果
- 研究类型:回顾性研究,样本量共73例(ARDS治疗前组24例、治疗后生存组17例、治疗后死亡组7例、对照组25例),单中心(江门市中心医院ICU)。
- 主要终点:肺部微生物组中病原微生物和背景菌的组间差异。
- 病原微生物:死亡组大肠埃希菌阳性率57.1%(4/7)vs. 生存组5.9%(1/17),P<0.05;死亡组白色念珠菌阳性率57.1%(4/7)vs. 生存组0%(0/7),P<0.05。
- 背景菌减少(可能为肺部益生菌/保护因素):Hydrobacter在ARDS治疗前组62.5%(15/24)vs. 生存组94.1%(16/17);死亡组14.3%(1/7)vs. 生存组94.1%(16/17);死亡组14.3%(1/7)vs. 对照组96.0%(24/25),均P<0.05。
- 背景菌增多(可能为潜在病原菌/死亡危险因素):肠杆菌目的爱德华菌属、肠杆菌科、埃希菌属、克雷伯菌属、克吕沃尔菌属、莱略特菌属、泛菌属、拉乌尔菌属在死亡组较治疗前组、生存组和对照组增多。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,肺部病原微生物中大肠埃希菌或白色念珠菌增多,或背景菌中肠杆菌目增多,可能是ARDS死亡的危险因素。
- 作者认为,背景菌Hydrobacter可能是ARDS生存的保护因素,能否作为新型治疗值得进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the differences and similarities of pre-treatment and post-treatment lung microbiome of acute respiratory distress syndrome (ARDS) and find out the change rules of the lung microbiome in the progression of ARDS according to different prognosis.
METHODS: A retrospective study was conducted. Patients with ARDS caused by severe pneumonia admitted to intensive care unit (ICU) of Jiangmen Central Hospital from February 2019 to January 2020 were enrolled as the study subjects. The patients were divided into pre-treatment (ARDS-preT) group (24 cases), post-treatment survival (ARDS-poT-Survival) group (17 cases), and post-treatment death (ARDS-poT-Dead) group (7 cases). ICU patients with mild pulmonary infection and non-ARDS admitted to ICU during the same period were enrolled as control group (25 cases). The similarities and differences of lung microbiome in four groups were analyzed and compared, and the possible pathogenic bacteria (potential risk factors for death) and probiotics (potential survival and protective factors) related to death caused by ARDS were screened.
RESULTS: In terms of pathogenic microorganisms, the positive rates of Escherichia coli and Candida albicans in the ARDS-poT-Dead group were significantly higher than those in the ARDS-poT-Survival group [57.1% (4/7) vs. 5.9% (1/17) and 57.1% (4/7) vs. 0% (0/7), both P < 0.05]. In the screening of background bacteria, the decrease of bacteria in the ARDS-preT group compared with the ARDS-poT-Survival group, the ARDS-poT-Dead group compared with the ARDS-poT-Survival group, the ARDS-poT-Dead group compared with the control group, the reduced bacteria might be pulmonary probiotics (potential protective factor for ARDS). The screening result was Hydrobacter [ARDS-preT group vs. ARDS-poT-Survival group: 62.5% (15/24) vs. 94.1% (16/17); ARDS-poT-Dead group vs. ARDS-poT-Survival group: 14.3% (1/7) vs. 94.1% (16/17); ARDS-poT-Dead vs. control: 14.3% (1/7) vs. 96.0% (24/25), all P < 0.05]. In the screening of background bacteria, the increase of bacteria in the ARDS-poT-Dead group compared with the ARDS-preT group, the ARDS-poT-Dead group compared with the ARDS-poT-Survival group, the ARDS-poT-Dead group compared with the control group, and the increased bacteria might be potential pulmonary pathogen (potential risk factor for death of ARDS), which belonged to Enterobacteria: Edwardsiella, Enterobacteriaceae, Escherichia, Klebsiella, Kluyvera, Lelliottia, Pantoea, Raoultella.
CONCLUSIONS: The results revealed the increase of Escherichia coli or Candida albicans in pulmonary pathogenic microorganisms, or the increase of Enterobacteria in background bacteria may be the risk factors for the death of ARDS. Additionally, background bacteria Hydrobacter probably is a protective factor for the survival of ARDS. Whether it can be used as a novel treatment for ARDS is worth further investigation.
参考来源
- Zhang P, Chen Y, Zheng W, et al. [Changes of lung microbiome of acute respiratory distress syndrome before and after treatment under open airway]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34839862. doi:10.3760/cma.j.cn121430-20210414-00558
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。